MiMedx Group, Inc. (MDXG)
3.21
-0.03
(-0.93%)
USD |
NASDAQ |
Nov 13, 16:00
3.20
-0.01
(-0.31%)
After-Hours: 19:59
MiMedx Group Enterprise Value : 347.63M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 347.63M |
| November 12, 2026 | 352.01M |
| November 11, 2026 | 363.68M |
| November 10, 2026 | 370.98M |
| November 09, 2026 | 363.68M |
| November 06, 2026 | 362.22M |
| November 05, 2026 | 357.84M |
| November 04, 2026 | 346.17M |
| November 03, 2026 | 353.47M |
| November 02, 2026 | 357.84M |
| October 30, 2026 | 445.40M |
| October 29, 2026 | 458.53M |
| October 28, 2026 | 455.62M |
| October 27, 2026 | 448.32M |
| October 26, 2026 | 441.02M |
| October 23, 2026 | 449.78M |
| October 22, 2026 | 452.70M |
| October 21, 2026 | 424.97M |
| October 20, 2026 | 496.47M |
| October 19, 2026 | 518.36M |
| October 16, 2026 | 525.66M |
| October 15, 2026 | 562.14M |
| October 14, 2026 | 565.06M |
| October 13, 2026 | 563.60M |
| October 12, 2026 | 584.03M |
| Date | Value |
|---|---|
| October 09, 2026 | 560.68M |
| October 08, 2026 | 553.39M |
| October 07, 2026 | 551.93M |
| October 06, 2026 | 553.39M |
| October 05, 2026 | 543.17M |
| October 02, 2026 | 549.01M |
| October 01, 2026 | 556.30M |
| September 30, 2026 | 559.22M |
| September 29, 2026 | 561.90M |
| September 28, 2026 | 563.36M |
| September 25, 2026 | 561.90M |
| September 24, 2026 | 567.73M |
| September 23, 2026 | 576.47M |
| September 22, 2026 | 599.79M |
| September 21, 2026 | 582.30M |
| September 18, 2026 | 576.47M |
| September 17, 2026 | 564.81M |
| September 16, 2026 | 570.64M |
| September 15, 2026 | 569.19M |
| September 14, 2026 | 557.53M |
| September 11, 2026 | 547.33M |
| September 10, 2026 | 551.70M |
| September 09, 2026 | 563.36M |
| September 08, 2026 | 561.90M |
| September 04, 2026 | 547.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 160.67M |
| Perspective Therapeutics, Inc. | -90.35M |
| T2 Biosystems, Inc. | -- |
| ABVC BioPharma, Inc. | 27.04M |
| Enovis Corp. | 2.929B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.683M |
| Revenue (Quarterly) | 62.28M |
| Total Expenses (Quarterly) | 70.97M |
| EPS Diluted (Quarterly) | -0.0595 |
| Gross Profit Margin (Quarterly) | 79.33% |
| Profit Margin (Quarterly) | -13.94% |
| Earnings Yield | -4.11% |
| Normalized Earnings Yield | -4.109 |